ArticleScientific reports2025
Role of miR-16, 146a, 19b and 720 gene expressions in the pathogenesis and diagnosis of vitiligo.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Epigenetic Modifications in Vitiligo.Clinical reviews in allergy & immunology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Vitiligo is a common long-term depigmenting skin disorder that is characterized by patches of skin losing their pigment. To evaluate serum/tissue levels of miR-16, 146a, 19b and 720 in vitiligo patients and healthy controls, also analyzing the correlations between all biomarkers to indicate whether those can be used to early diagnose vitiligo patients. Forty-subjects were included, divided into two equal groups, 20 healthy matched individuals and 20 vitiligo patients. For all groups a 5 mL venous blood sample for serum isolation was taken and analyzed for the serum level of miRNAs. For tissue analysis, 3 mm biopsy was taken. For all patients Vitiligo area scoring index (VASI), vitiligo disease activity (VIDA), disease duration and extent percentages were calculated. No significant difference was observed in age and sex ratio among the two groups (p > 0.05). Serum, expression levels for miR-16, 146a, and 19b were overexpressed in vitiligo patients as compared to healthy controls with p-value 0.000 for all biomarkers. While miR-720 was reported low in vitiligo patients compared to controls (p = 0.000). For tissue samples, miR-16, 146a, 19b were overexpressed in vitiligo patients with p-values 0.000, 0.000 and < 0.001 respectively, while for the expression level of miR-720 in tissue, the level was low compared to controls (p = 0.000). There are positive correlations between VASI and miR-16, 146a in serum and miR-146a in tissue. Also positive correlations between disease extent and both miR-16 and miR-146a in serum and in tissue was found. A negative correlation between VIDA and miR-720 in serum was found. Various correlations between the selected miRNAs were reported. Based upon the expression levels of miR-16, 146a, 19b and 720 in both serum and tissue, these biomarkers can be used as early indicators for vitiligo.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.